News

A REDUCE-IT analysis highlights consistent cardiovascular benefits with icosapent ethyl across varying levels of Lp(a).

In a new study, investigators evaluated if social contact influenced the age gap between biological age, estimated with artificial intelligence (AI), and chronological age.

The post-hoc analysis found tenapanor significantly improved weekly scores for abdominal pain, discomfort, and bloating, as measured by the Abdominal Score.

Adults with higher triglyceride levels exhibit a higher prevalence of chronic conditions and multi-organ disease.

The FDA identified high concentration of lidocaine across marketed, over-the-counter topical products from 6 different companies.

A study in China identified a negative and non-linear relationship between hemoglobin levels and a renal composite end point in patients with DKD.

In this analysis from the UK, the DDPS led to improved pathway management which also achieved lower service demand and smaller waiting lists for dermatologists.

In this episode, hosts discuss top news and updates in automated insulin delivery from ATTD 2024, with a focus on new data from the T1D Exchange and a read-out from the CRISTAL study.

In a recent UK study, more than half of stroke survivors developed depression within 18 years.

The hospitalization risk was reduced to up to 75% for patients with heart disease treated with both antidepressants and psychotherapy to manage anxiety or depression symptoms.

A hypothetical triennial blood-based screening test meeting Centers for Medicare and Medicaid Services coverage criteria was cost-effective versus no screening but not compared to FIT, sDNA-FIT, or colonoscopy.

Deepak Sambhara, MD, discusses how clinical practice has responded to the introduction of aflibercept 8 mg and the significance of extended treatment intervals for patients with retinal diseases.

Chronic kidney disease was linked to increased mortality, higher costs, and the need for mechanical ventilation among hospitalized patients with sickle cell disease.

This clinical quiz will test your knowledge on the use of non-statin therapies for LDL-C lowering based on the American College of Cardiology's 2022 Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.

Patients with cirrhosis had greater health care costs than matched controls, attributed mostly to cirrhosis complications and high inpatient utilization in the first year after diagnosis.

The SYMPHONY trial found reboxetine can significantly reduce cataplexy, excessive daytime sleepiness, cognitive impairment, depression, and anxiety for patients with narcolepsy.

Michael Weber, MD, lead of the PRECISION trial, discusses the significance of the aprocitentan (Tryvio) approval and key points for providers who may have patients with uncontrolled hypertension.

With limited CBTi-trained psychologists, investigators assessed the effectiveness of a self-guided digital CBTi as another option, so people don’t have to turn to pills.

Both high blood pressure and triglycerides were identified as risk factors for IgAN, although high blood pressure was deemed to have the most direct influence.

Presence of nephritis in SLE patients is linked to higher cardiovascular risk factors and 3-fold increase in incidence of cardiovascular mortality.

A significant association between Lp(a) and adverse cardiovascular outcomes was altered by renal function in patients undergoing percutaneous coronary intervention.

This segment of Cohen’s interview from AAD covered the other talk given by Cohen titled ‘Knowing Lichenoid Dermatoses: Common Pathways and Treatments.’

Implementing a Food as Medicine program improved diet, physical activity, and reduced cardiovascular risk factors among participants.

The approval marks the first and only once-daily single-tablet combination therapy for patients with pulmonary arterial hypertension.

David M. Brown, MD, discusses the full one-year data from the PULSAR and PHOTON trials and the implications of aflibercept 8 mg for patients with AMD and DME.

The FDA's approval of the label expansion for bempedoic acid to include cardiovascular risk reduction is based on data from the CLEAR Outcomes trial.

NCX 470 0.1% eye drops reduced IOP more than latanoprost in individuals with open-angle glaucoma or ocular hypertension in the phase 3 Mont Blanc trial.

In this post-AAD interview, Cohen discusses his contribution to the presentation titled ‘Psoriasis: Modern Therapeutic Approaches.’